This was the stock's fourth consecutive day of losses.

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of ...

LVM Capital Management Ltd. MI lifted its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.4% in the 4th quarter, ...

Graypoint LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.1% during the 4th quarter, according ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...